Support line (toll-free) (844) 835-4325 | Events help (608) 828-8852 | Community

Free To Breathe - A Partnership For Lung Cancer Survival

participant Login

News

Featured Clinical Trial of the Week: Targeting ALK After Other Treatments Unsuccessful 

  • November 01 2013

    Share |
    Featured Clinical Trial of the Week: Targeting ALK After Other Treatments Unsuccessful 

    An already-approved drug, crizotinib (Xalkori®), is available to treat patients with ALK mutation-positive lung cancer. However, many patients' tumors become resistant to crizotinib over time, and their cancers begin growing again.

    This clinical trial tests the effectiveness of LDK378, a drug that targets the ALK mutation in non-small cell lung cancer, to see if it can treat crizotinib-resistant tumors. Among 82 patients in a previous study who had crizotinib-resistant lung cancer, 44 experienced shrinkage of their cancer after treatment with LDK378. One patient even experienced a complete response—no evidence of disease.

    Eligibility
    This trial is open to non-small cell lung cancer patients whose cancer has progressed during therapy with crizotinib.

    Visit ClinicalTrials.gov for more information on this trial.

    If you’re looking for further information on this and/or other lung cancer clinical trials, please contact our Clinical Trials Matching Service, where trained representatives will match your particular cancer and health issues to clinical trials that are available for you.

    0 comments

Leave a comment

Comment Guidelines

Basic HTML formatting permitted -
<ul>, <li>, <strong>, <em>, <a href>, <blockquote>, <code>

©2017 Free To Breathe | Lung Cancer Research Foundation | Federal Tax ID #14-1935776 | LCRF is a 501(c)(3) public charity.